November 6th 2024
Surveyed individuals who identified as a racial or ethnic minority reported difficulties discussing cancer diagnosis and treatment.
November 1st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Loperamide Plus Budesonide Lessons Diarrhea With Neratinib in HER2+ Breast Cancer
December 9th 2016According to findings from a phase II trial, prophylactic treatment with a combination of loperamide and budesonide reduced the rate of all-grade diarrhea associated with neratinib to 65%, compared with 95.4% observed in the ExteNET trial.
Everolimus/Fulvestrant Combo Improves Survival in HR+ Breast Cancer
December 8th 2016According to phase II trial findings, adding everolimus to fulvestrant significantly improved progression-free survival for postmenopausal patients with metastatic hormone receptor-positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.
The Elephant in the Pink Room: Living With Metastatic Breast Cancer
October 14th 2016When Breast Cancer Awareness Month arrives each October, for many women there is a lot to be thankful for. Research advances have led to less aggressive treatment options and a good prognosis for women with early-stage disease, but for women with metastatic breast cancer (MBC), it is a different story.
Patients With Metastatic Breast Cancer Want Better Communication With Providers
October 14th 2016In 2014, Novartis Oncology commissioned the Harris Poll to conduct the Make Your Dialogue Count survey to identify the emotional needs of patients newly diagnosed with metastatic breast cancer as well as during treatment change.